# A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

> **NCT04539938** · PHASE2 · COMPLETED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 70 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** tucatinib
- **DRUG:** trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT04539938
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2024-07-15
- **Final completion:** 2025-03-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539938, "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04539938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*